Zurich, Switzerland, December 2023 – Venture Valuation announces that it has appointed Bill Colihan and David Tucker as BD Directors to strengthen its expansion in North America. The new appointments’ primary focus will be on Venture Valuation’s Biotechgate database, a unique business development and licensing platform for the life sciences industry.
Both BD directors are located in the USA and will take care of the North American market. Bill Colihan has extensive experience in the business development of innovative information services and previously served as President of Knowledge Express. He holds a BA from the University of Delaware and an MBA from Villanova University.
David Tucker combines an investment banking background with 15 years of experience in life science business development, leadership and consulting. He graduated from Colorado State University with an MBA and is currently pursuing a Master’s degree in Biotechnology from Johns Hopkins University.
Together with the existing sales teams in Asia and Europe, Biotechgate now covers all time zones and thus enables an even better service for all customers and partners. “I’m thrilled to welcome Bill and David to the team as we continue to grow our presence and better serve our North America-based clients. Both possess strong skillsets and a wealth of previous experience in BD intelligence that will be a valuable asset to our company going forward,” said Patrik Frei, chief executive officer of Venture Valuation.
If you wish to get in touch with the North American sales team, you can reach out through the Biotechgate website or by connecting with them on LinkedIn:
- Bill Colihan, BD Director US-East
- David Tucker, BD Director US-West
About Venture Valuation:
Venture Valuation was founded in 1999 based on profound research work by the founder and CEO, Dr. Patrik Frei, at the University of St. Gallen (HSG) and the Swiss Federal Institute of Technology in Lausanne (EPFL). The company has remained true to its mission: the independent assessment and valuation of companies, products and assets.
The focus lies on technology companies in fast-growing markets and industries including pharmaceuticals, biotechnology (Biotech), medical technology (MedTech), nanotechnology, renewable energies (cleantech) and information technology (IT) / computer science / software. Clients include both, investors as well as finance-seeking companies themselves, and are domiciled on almost all continents. Over the course of more than two decades, key strengths and expertise have been built in the life sciences industry.
About Biotechgate:
Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 70,000 life science company profiles. Thanks to its unique data-sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 30,000 licensing deals and a clinical trials database containing over 800,000 records from registries around the world.